sk&f-38393 has been researched along with ibopamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Girbes, AR; Smit, AJ; van Veldhuisen, DJ | 1 |
| Casagrande, C; La Regina, A; Merlo, L | 1 |
| Hasenfuss, G; Just, H | 1 |
2 review(s) available for sk&f-38393 and ibopamine
| Article | Year |
|---|---|
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dopamine Agents; Fenoldopam; Heart Failure; Humans; Levodopa; Receptors, Dopamine | 1990 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; Deoxyepinephrine; Dopamine Agents; Fenoldopam; Heart Failure; Humans; Levodopa; Vasodilator Agents | 1989 |
1 other study(ies) available for sk&f-38393 and ibopamine
| Article | Year |
|---|---|
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenoldopam; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic | 1991 |